Effects of different up-dosing regimens for hymenoptera venom immunotherapy on serum CTLA-4 and IL-10.
<h4>Background</h4>Cytotoxic T lymphocyte associated antigen-4 (CTLA-4) is involved in the activation pathways of T lymphocytes. It has been shown that the circulating form of CTLA-4 is elevated in patients with hymenoptera allergy and can be down regulated by immunotherapy.<h4>Obj...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/aedc9dbda2934a46937da33a83235dbf |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:aedc9dbda2934a46937da33a83235dbf |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:aedc9dbda2934a46937da33a83235dbf2021-11-18T07:15:04ZEffects of different up-dosing regimens for hymenoptera venom immunotherapy on serum CTLA-4 and IL-10.1932-620310.1371/journal.pone.0037980https://doaj.org/article/aedc9dbda2934a46937da33a83235dbf2012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22723841/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Cytotoxic T lymphocyte associated antigen-4 (CTLA-4) is involved in the activation pathways of T lymphocytes. It has been shown that the circulating form of CTLA-4 is elevated in patients with hymenoptera allergy and can be down regulated by immunotherapy.<h4>Objective</h4>to assess the effects on CTLA-4 of venom immunotherapy, given with different induction protocols: conventional (6 weeks), rush (3 days) or ultra rush (1 day).<h4>Methods</h4>Sera from patients with hymenoptera allergy were collected at baseline and at the end of the induction phase. CTLA-4 and IL-10 were assayed in the same samples. A subset of patients were assayed also after 12 months of VIT maintenance.<h4>Results</h4>Ninety-four patients were studied. Of them, 50 underwent the conventional induction, 20 the rush and 24 the ultra-rush. Soluble CTLA-4 was detectable in all patients at baseline, and significantly decreased at the end of the induction, irrespective of its duration. Of note, a significant decrease of sCTLA-4 could be seen already at 24 hours. In parallel, IL-10 significantly increased at the end of the induction. At 12 months, sCTLA-4 remained low, whereas IL-10 returned to the baseline values.<h4>Conclusions</h4>Serum CTLA4 is an early marker of the immunological effects of venom immunotherapy, and its changes persist after one year of maintenance treatment.Anna Maria RiccioDaniele SaverinoGiampaola PesceAnthi RogkakouMaurizio SeverinoPatrizia BonadonnaErminia RidoloMarina MauroGiorgio Walter CanonicaMarcello BagnascoGiovanni PassalacquaPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 6, p e37980 (2012) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Anna Maria Riccio Daniele Saverino Giampaola Pesce Anthi Rogkakou Maurizio Severino Patrizia Bonadonna Erminia Ridolo Marina Mauro Giorgio Walter Canonica Marcello Bagnasco Giovanni Passalacqua Effects of different up-dosing regimens for hymenoptera venom immunotherapy on serum CTLA-4 and IL-10. |
| description |
<h4>Background</h4>Cytotoxic T lymphocyte associated antigen-4 (CTLA-4) is involved in the activation pathways of T lymphocytes. It has been shown that the circulating form of CTLA-4 is elevated in patients with hymenoptera allergy and can be down regulated by immunotherapy.<h4>Objective</h4>to assess the effects on CTLA-4 of venom immunotherapy, given with different induction protocols: conventional (6 weeks), rush (3 days) or ultra rush (1 day).<h4>Methods</h4>Sera from patients with hymenoptera allergy were collected at baseline and at the end of the induction phase. CTLA-4 and IL-10 were assayed in the same samples. A subset of patients were assayed also after 12 months of VIT maintenance.<h4>Results</h4>Ninety-four patients were studied. Of them, 50 underwent the conventional induction, 20 the rush and 24 the ultra-rush. Soluble CTLA-4 was detectable in all patients at baseline, and significantly decreased at the end of the induction, irrespective of its duration. Of note, a significant decrease of sCTLA-4 could be seen already at 24 hours. In parallel, IL-10 significantly increased at the end of the induction. At 12 months, sCTLA-4 remained low, whereas IL-10 returned to the baseline values.<h4>Conclusions</h4>Serum CTLA4 is an early marker of the immunological effects of venom immunotherapy, and its changes persist after one year of maintenance treatment. |
| format |
article |
| author |
Anna Maria Riccio Daniele Saverino Giampaola Pesce Anthi Rogkakou Maurizio Severino Patrizia Bonadonna Erminia Ridolo Marina Mauro Giorgio Walter Canonica Marcello Bagnasco Giovanni Passalacqua |
| author_facet |
Anna Maria Riccio Daniele Saverino Giampaola Pesce Anthi Rogkakou Maurizio Severino Patrizia Bonadonna Erminia Ridolo Marina Mauro Giorgio Walter Canonica Marcello Bagnasco Giovanni Passalacqua |
| author_sort |
Anna Maria Riccio |
| title |
Effects of different up-dosing regimens for hymenoptera venom immunotherapy on serum CTLA-4 and IL-10. |
| title_short |
Effects of different up-dosing regimens for hymenoptera venom immunotherapy on serum CTLA-4 and IL-10. |
| title_full |
Effects of different up-dosing regimens for hymenoptera venom immunotherapy on serum CTLA-4 and IL-10. |
| title_fullStr |
Effects of different up-dosing regimens for hymenoptera venom immunotherapy on serum CTLA-4 and IL-10. |
| title_full_unstemmed |
Effects of different up-dosing regimens for hymenoptera venom immunotherapy on serum CTLA-4 and IL-10. |
| title_sort |
effects of different up-dosing regimens for hymenoptera venom immunotherapy on serum ctla-4 and il-10. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2012 |
| url |
https://doaj.org/article/aedc9dbda2934a46937da33a83235dbf |
| work_keys_str_mv |
AT annamariariccio effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10 AT danielesaverino effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10 AT giampaolapesce effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10 AT anthirogkakou effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10 AT maurizioseverino effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10 AT patriziabonadonna effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10 AT erminiaridolo effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10 AT marinamauro effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10 AT giorgiowaltercanonica effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10 AT marcellobagnasco effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10 AT giovannipassalacqua effectsofdifferentupdosingregimensforhymenopteravenomimmunotherapyonserumctla4andil10 |
| _version_ |
1718423748726489088 |